Avicanna Reports Study Results in Epidermolysis Bullosa Patients

Avicanna Inc., a biopharmaceutical company dedicated to the development and commercialization of cannabinoid-based products, has successfully completed a retrospective observational study utilizing its RHO Phyto™ branded Ultra CBD Topical Cream on patients with epidermolysis bullosa (EB). This study, led by Dr. Elena Pope, Head of Dermatology at The Hospital for Sick Children in Toronto, assessed the cream's efficacy and tolerability in the context of wound healing, pain, and itch management for EB patients.

The study involved 20 participants, comprising 14 males and 6 females, with an average age of 17.3 years. These patients had different subtypes of EB: 60% had dystrophic EB, 30% had simplex EB, and 10% had junctional EB. Over a month of daily application of the 3% CBD cream, 55% of participants reported improvements in wound healing, while 45% maintained wound stability. Additionally, 65% of the patients reported reductions in itch, and 50% experienced pain relief. Notably, 45% of the study’s participants continued using the treatment for more than six months.

The study's findings will be shared at Avicanna's symposium on May 13th by Dr. Camila Sofia Arriaga Egnen from The Hospital for Sick Children. Dr. Elena Pope emphasized that the RHO Phyto™ branded Ultra CBD Topical Cream presents a new topical therapeutic option for EB patients, potentially aiding in wound healing and providing symptom relief with good tolerability. She also indicated the necessity for further prospective studies to validate these preliminary findings.

Dr. Karolina Urban, Executive Vice President of Medical Affairs at Avicanna, expressed her satisfaction with the study’s early positive results, noting their importance in guiding the future development of the company’s medical products and pharmaceutical pipeline.

Epidermolysis bullosa (EB) is a rare group of inherited disorders characterized by extremely fragile skin, leading to blistering and tearing. In the United States, the incidence of EB is approximately 19 per million live births, with a prevalence of 8 per million. EB severity can range from mild skin involvement to severe cases affecting multiple systems and reducing life expectancy. Current treatments are palliative, focusing on promoting patient well-being, optimizing wound healing, and managing secondary complications.

Avicanna Inc. operates on an international scale, focusing on the advancement and commercialization of cannabinoid-based products for the medical and pharmaceutical markets. The company has developed a scientific platform that includes research and development (R&D) and clinical development, leading to the commercialization of more than thirty proprietary products. These products support four main business pillars: the Medical Cannabis formulary (RHO Phyto™), the medical cannabis care platform (MyMedi.ca), pharmaceutical products (Trunerox™), and active pharmaceutical ingredients (Aureus Santa Marta™).

The RHO Phyto™ formulary includes a variety of products for oral, sublingual, topical, and transdermal applications, available across Canada and expanding internationally. MyMedi.ca aims to enhance the patient journey with medical cannabis, providing educational resources and bilingual pharmacist-led support programs. Avicanna’s pharmaceutical products, such as Trunerox™, target unmet medical needs in dermatology, chronic pain, and neurological disorders, with clinical trials underway. The company’s subsidiary, Santa Marta Golden Hemp SAS, supplies high-quality active pharmaceutical ingredients (API) for various uses, contributing to Avicanna’s global supply chain.